Cebranopadol, a pain relief drug, showed low potential for abuse among nondependent recreational opioid users compared with tramadol or oxycodone, researchers from Tris Pharma Inc. stated in a press release.
“Cebranopadol is a novel pain medication and works in a fundamentally different way by being an agonist to this [nociceptin/orphanin FQ peptide] receptor, which is new, as well as more traditional receptors,” James Hackworth, PhD, BS, president of brand division at Tris Pharma, told Healio.
According to the release, multiple clinical studies have demonstrated that cebranopadol